Literature DB >> 30230544

Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.

Qi Chen1, Xueqiang Liu2, Zhesi Luo1, Shisi Wang2, Jialin Lin2, Zheng Xie1, Mengge Li1, Chunmei Li1, Hua Cao3, Qingsong Huang1, Jianwen Mao1, Bin Xu1,2.   

Abstract

Chloride channel-3 (ClC-3), a member of the ClC family of voltage-gated Cl- channels, is involved in the resistance of tumor cells to chemotherapeutic drugs. Here, we report a new mechanism for ClC-3 in mediating multidrug resistance (MDR). ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells. Changes in the ClC-3 expression resulted in the development of drug resistance in formerly drug-sensitive A549 or MCF-7 cells, and drug sensitivity in formerly drug-resistant A549/Taxol and MCF-7/DOX cells. Double transgenic MMTV-PyMT/CLCN3 mice with spontaneous mammary cancer and ClC-3 overexpression demonstrated drug resistance to PTX and DOX. ClC-3 expression upregulated the expression of MDR1 messenger RNA and P-gp by activating the nuclear factor-κB (NF-κB)-signaling pathway. These data suggest that ClC-3 expression in cancer cells induces MDR by upregulating NF-κB-signaling-dependent P-gp expression involving another new mechanism for ClC-3 in the development of drug resistance of cancers.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  P-glycoprotein; cancer; chemotherapy; chloride channel-3; multidrug resistance

Mesh:

Substances:

Year:  2018        PMID: 30230544     DOI: 10.1002/jcp.27402

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  8 in total

Review 1.  Ion Channels in Lung Cancer.

Authors:  Etmar Bulk; Luca Matteo Todesca; Albrecht Schwab
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

2.  CD44-targeted hyaluronic acid-curcumin reverses chemotherapeutics resistance by inhibiting P-gp and anti-apoptotic pathways.

Authors:  Lu Diao; Ao Shen; Yunxu Yang; Jin Tao; Ying Hu
Journal:  RSC Adv       Date:  2019-12-11       Impact factor: 4.036

Review 3.  Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer.

Authors:  Wenxiao Jiang; Guiqing Cai; Peter Hu; Yue Wang
Journal:  Acta Pharm Sin B       Date:  2021-02-10       Impact factor: 11.413

4.  SOX2 regulates paclitaxel resistance of A549 non‑small cell lung cancer cells via promoting transcription of ClC‑3.

Authors:  Youwei Huang; Xiangyu Wang; Rendong Hu; Guopeng Pan; Xi Lin
Journal:  Oncol Rep       Date:  2022-09-07       Impact factor: 4.136

5.  ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.

Authors:  Zhuoyu Gu; Liping Wang; Xiaohan Yao; Qian Long; Kaping Lee; Jieyao Li; Dongli Yue; Shuangning Yang; Yanfen Liu; Na Li; Yixin Li
Journal:  Cell Death Dis       Date:  2020-10-22       Impact factor: 8.469

6.  An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.

Authors:  Mohammad Sultan; Jacob T Nearing; Justin M Brown; Thomas T Huynh; Brianne M Cruickshank; Emily Lamoureaux; Dejan Vidovic; Margaret L Dahn; Wasundara Fernando; Krysta M Coyle; Carman A Giacomantonio; Morgan G I Langille; Paola Marcato
Journal:  Mol Oncol       Date:  2021-05-18       Impact factor: 6.603

Review 7.  The Role of Chloride Channels in the Multidrug Resistance.

Authors:  Bartosz Wilczyński; Alicja Dąbrowska; Jolanta Saczko; Julita Kulbacka
Journal:  Membranes (Basel)       Date:  2021-12-28

8.  ClC-c regulates the proliferation of intestinal stem cells via the EGFR signalling pathway in Drosophila.

Authors:  Jinping Huang; Xiao Sheng; Zhangpeng Zhuo; Danqing Xiao; Kun Wu; Gang Wan; Haiyang Chen
Journal:  Cell Prolif       Date:  2021-12-24       Impact factor: 8.755

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.